

USSN 09/554,533  
Atty Docket No. 238/086US

### AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

**Listing of Claims:**

1-54. (Canceled)

55. (New) A peptide compound of the formula:

His Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Thr Phe Thr Xaa<sub>8</sub> Asp Xaa<sub>10</sub>  
Ser Lys Gln Xaa<sub>14</sub> Glu Glu Glu Ala Val Arg  
Leu Xaa<sub>22</sub> Xaa<sub>23</sub> Glu Xaa<sub>25</sub> Leu Lys Xaa<sub>28</sub> Gly Gly  
Pro Ser Ser Gly Ala Pro Pro Pro-Z,

wherein Xaa<sub>2</sub> is Ser, Gly or Thr,

Xaa<sub>3</sub> is Asp or Glu,

Xaa<sub>8</sub> is Ala, Ser, or Thr,

Xaa<sub>10</sub> is Leu, Ile, Val, pentylglycine or Met,

Xaa<sub>14</sub> is Ala, Leu, Ile, pentylglycine, Val or Met,

Xaa<sub>22</sub> is Phe, Tyr or naphthylalanine,

Xaa<sub>23</sub> is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met,

Xaa<sub>25</sub> is Ala, Trp, Phe, Tyr or naphthylalanine,

Xaa<sub>28</sub> is Ala or Asn, and

Z is -OH or -NH<sub>2</sub>; and

pharmaceutically acceptable salts thereof.

56. (New) The peptide compound of claim 55, wherein Xaa<sub>2</sub> is Ser.

57. (New) The peptide compound of claim 55, wherein Xaa<sub>2</sub> is Gly.

58. (New) The peptide compound of claim 55, wherein Xaa<sub>3</sub> is Asp.

USSN 09/554,533  
Atty Docket No. 238/086US

59. (New) The peptide compound of claim 55, wherein Xaa<sub>14</sub> is Leu.

60. (New) The peptide compound of claim 55, wherein Xaa<sub>25</sub> is Phe.

61. (New) The peptide compound of claim 55, wherein Xaa<sub>28</sub> is Ala.

62. (New) The peptide compound of claim 55, wherein Z is NH<sub>2</sub>.

63. (New) A peptide compound of the formula:

His Gly Glu Gly Thr Phe Thr Ser Asp Leu

Ser Lys Gln Xaa<sub>14</sub> Glu Glu Glu Ala Val Arg

Leu Phe Ile Glu Xaa<sub>25</sub> Leu Lys Asn-NH<sub>2</sub>;

wherein Xaa<sub>14</sub> is Ala, Leu, Ile, pentylglycine, Val or Met;

Xaa<sub>25</sub> is Ala, Trp, Phe, Tyr or naphthylalanine; and

wherein any one amino acid other than Xaa<sub>4</sub>, Xaa<sub>7</sub>, Xaa<sub>9</sub>, Xaa<sub>14</sub>, Xaa<sub>18</sub>, Xaa<sub>22</sub> and Xaa<sub>23</sub>

optionally is Ala; and pharmaceutically acceptable salts thereof.

64. (New) The peptide compound of claim 63, wherein Xaa<sub>14</sub> is Leu.

65. (New) The peptide compound of claim 63, wherein Xaa<sub>25</sub> is Phe.

66. (New) A peptide compound of the formula:

His Xaa<sub>2</sub> Xaa<sub>3</sub> Gly Thr Phe Thr Ser Asp Leu

Ser Lys Gln Met Glu Glu Glu Ala Val Arg

Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly

Pro Ser Ser Gly Ala Pro Pro Pro-Z,

wherein Xaa<sub>2</sub> is Gly, Ser, Ala or Thr, Xaa<sub>3</sub> is Glu or Asp; and Z is -OH or NH<sub>2</sub>; and pharmaceutically acceptable salts thereof.

67. (New) The peptide compound of claim 66, wherein Xaa<sub>2</sub> is Ser.

USSN 09/554,533  
Atty Docket No. 238/086US

68. (New) The peptide compound of claim 66, wherein Xaa<sub>3</sub> is Asp.

69. (New) The peptide compound of claim 66, wherein Z is NH<sub>2</sub>.

70. (New) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 55.

71. (New) The method of claim 70 further comprising the administration of a therapeutically effective amount of an insulin.

72. (New) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 63.

73. (New) The method of claim 72 further comprising the administration of a therapeutically effective amount of an insulin.

74. (New) A method for the treatment of diabetes mellitus comprising the administration of a therapeutically effective amount of a compound according to claim 66.

75. (New) The method of claim 74 further comprising the administration of a therapeutically effective amount of an insulin.